文献速递帕金森病与运动障碍

远程神经康复对帕金森病运动与非运动症状及生活质量的影响:TELEPARK随机临床试验

Teleneurorehabilitation and Motor and Nonmotor Symptoms and Quality of Life in Parkinson Disease: The TELEPARK Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2025-02-24

TELEPARK单中心、评估者盲法随机临床试验纳入63例帕金森病患者,比较远程神经康复与面对面康复。两组干预后MDS-UPDRS III评分变化无显著差异(远程组-6.74 vs 面对面组-7.54,P=0.39),非运动症状量表与生活质量问卷变化相似,远程神经康复安全有效。

要点

  • 远程神经康复组干预后MDS-UPDRS III评分较基线显著降低(35.17 vs 28.6,P=0.001)。
  • 两组干预后MDS-UPDRS III评分变化无显著差异(远程组-6.74 vs 面对面组-7.54,P=0.39)。
  • 非运动症状量表和生活质量问卷评分变化在两组间相似。

核心结论

  • 远程神经康复对印度帕金森病患者改善运动症状、非运动症状和生活质量安全有效。

研究设计与样本

  • TELEPARK为单中心、评估者盲法随机临床试验,2020年9月至2021年7月开展,历时11个月,随访12周,最终数据可于2024年7月1日分析。
  • 纳入18岁及以上、诊断为特发性帕金森病、Hoehn和Yahr分期1至2.5期、简易精神状态检查评分24分或以上且拥有可视频通话智能手机的患者,随机分配至面对面治疗组或远程神经康复组。
  • 面对面组每周面对面接受物理治疗、有氧运动和呼吸练习30分钟,持续4周,之后每2周1次,持续8周;远程神经康复组第1天面对面,随后通过视频通话监督,前4周每周1次,之后每2周1次,持续8周。
  • 共63例参与者被分析(面对面组28例,远程神经康复组35例)。

主要发现

  • 面对面组平均(标准差)年龄为60.50(7.08)岁,远程神经康复组为62.80(12.46)岁。
  • 面对面组女性12/28例(42.9%),远程神经康复组女性16/35例(45.7%)。
  • 远程神经康复组干预后MDS-UPDRS III平均(标准差)评分较干预前显著降低(干预前35.17[17.72] vs 干预后28.6[19.7];P=0.001)。
  • 干预后MDS-UPDRS III评分平均(标准差)变化两组间无显著差异(远程神经康复组-6.74[11.07] vs 面对面组-7.54[10.52];P=0.39)。
  • 非运动症状量表(NMSS)和帕金森病问卷-8汇总指数(PDQ8-SI)评分中位变化两组间相似。

关键数值与推荐

  • 纳入标准:年龄18岁或以上,特发性帕金森病,Hoehn和Yahr分期1至2.5期,简易精神状态检查评分24分或以上,拥有可视频通话的智能手机。

临床怎么用

  • 远程神经康复可作为帕金森病患者改善运动症状、非运动症状和生活质量的 safe and effective 选择(作者结论)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: To our knowledge, no randomized clinical trials have compared the efficacy and safety of teleneurorehabilitation (TNR) with in-person rehabilitation in Parkinson disease (PD) during the COVID-19 pandemic lockdown. OBJECTIVE: To assess the efficacy and safety of TNR among patients with PD during the COVID-19 lockdown. DESIGN, SETTING, AND PARTICIPANTS: The TELEPARK single-center, assessor-blinded, randomized clinical trial was conducted over 11 months from September 2020 to July 2021, with follow-up after 12 weeks. Final data could be analyzed on July 1, 2024. Patients aged 18 years or older diagnosed with idiopathic PD with Hoehn and Yahr stage 1 to 2.5, Mini-Mental State Examination score of 24 or higher, and who possessed a smartphone allowing videocalling were eligible for inclusion and randomized to in-person or TNR therapy. INTERVENTION: The in-person group received physiotherapy, aerobic, and breathing exercises for 30 minutes in person once a week for 4 weeks and then once every 2 weeks for 8 weeks. The TNR group received in-person sessions on day 1, followed by supervised sessions via videocalling once a week for the first 4 weeks, then once every 2 weeks for 8 weeks. MAIN OUTCOME AND MEASURES: The primary outcome was mean change in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale III (MDS-UPDRS III) postintervention score from baseline. Mean changes in postintervention MDS-UPDRS II and III, Non-Motor Symptom Scale (NMSS), Parkinson's Disease Questionnaire-8 Summary Index (PDQ8-SI), 6-minute walk test (6MWT), and functional reach test (FRT) scores from baseline between groups was assessed using unpaired t tests. RESULTS: A total of 63 participants (28 in-person and 35 TNR) were analyzed. Mean (SD) ages in the in-person and TNR groups were 60.50 (7.08) years and 62.80 (12.46) years, respectively. Twelve of 28 patients in the in-person group (42.9%) and 16 of 35 patients in the TNR group (45.7%) were female. Mean (SD) MDS-UPDRS III scores were significantly lower following TNR (pre-TNR: 35.17 [17.72] vs post-TNR: 28.6 [19.7]; P = .001). Mean (SD) change in postintervention MDS-UPDRS III scores was not significantly different between the 2 groups (TNR: -6.74 [11.07] vs in-person: -7.54 [10.52]; P = .39). Median changes in NMSS and PDQ8-SI scores were similar between the groups. CONCLUSIONS AND RELEVANCE: TNR is safe and effective in improving motor and nonmotor symptoms and quality of life among Indian patients with PD.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Dhamija RK, Saluja A, Garg D, et al. Teleneurorehabilitation and Motor and Nonmotor Symptoms and Quality of Life in Parkinson Disease: The TELEPARK Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 39992667. doi:10.1001/jamaneurol.2024.5387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。